肝细胞癌靶向治疗研究进展

doi:10.24920/003737

摘要/Abstract

摘要：

肝细胞癌（Hepatocellular carcinoma,HCC）是常见的恶性肿瘤之一,治疗手段有限。随着肝癌发生发展过程中关键基因和信号通路认识的深入,一些高选择性、低毒性的靶向药物不断问世,为晚期肝癌的治疗带来了多种选择。本文综述了肝细胞癌靶向治疗的代表性药物和潜在靶点的研究进展。

关键词: 肝细胞癌, 靶向治疗, 基因, 信号通路, 药物

Abstract:

Hepatocellular carcinoma (HCC) is one of the most common malignancies, and its treatment is limited. With the understanding of key genes and signaling pathways in the occurrence and development of HCC, targeted drugs with high selectivity and low toxicity have been developed continuously, bringing a variety of options for the treatment of advanced HCC. In this article, the research progress on representative drugs of targeted therapy and potential therapeutic targets for HCC are reviewed.

Key words: hepatocellular carcinoma, targeted therapy, genes, signaling pathway, drug

基金资助: 湖南省卫生计生委科研课题(A2017015)

Qiong Chen,Xuefeng Yang. Research Progress in Targeted Therapy of Hepatocellular Carcinoma[J].Chinese Medical Sciences Journal, 2021, 36(1): 57-65.

参考文献 70.

1.	Yang JD, Hainaut P, Gores GJ, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol, 2019; 16(10):589-604. doi: 10.1038/s41575-019-0186-y. doi: 10.1038/s41575-019-0186-y pmid: 31439937
2.	Wang H, Lu Z, Zhao X. Tumorigenesis, diagnosis, and therapeutic potential of exosomes in liver cancer. J Hematol Oncol 2019; 12(1):133. doi: 10.1186/s13045-019-0806-6. doi: 10.1186/s13045-019-0806-6 pmid: 31815633
3.	Llovet JM, Montal R, Sia D, et al. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol 2018; 15(10):599-616. doi: 10.1038/s41571-018-0073-4. doi: 10.1038/s41571-018-0073-4 pmid: 30061739
4.	Couri T, Pillai A. Goals and targets for personalized therapy for HCC. Hepatol Int 2019; 13(2):125-37. doi: 10.1007/s12072-018-9919-1. doi: 10.1007/s12072-018-9919-1 pmid: 30600478
5.	Pinter M, Peck-Radosavljevic M. Review article: systemic treatment of hepatocellular carcinoma. Aliment Pharmacol Ther 2018; 48(6):598-609. doi: 10.1111/apt.14913. doi: 10.1111/apt.14913 pmid: 30039640
6.	Li M, Su Y, Zhang F, et al. A dual-targeting reconstituted high density lipoprotein leveraging the synergy of sorafenib and antimiRNA21 for enhanced hepatocellular carcinoma therapy. Acta Biomater 2018; 75:413-26. doi: 10.1016/j.actbio.2018.05.049. doi: 10.1016/j.actbio.2018.05.049 pmid: 29859368
7.	Matsuki M, Hoshi T, Yamamoto Y, et al. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Med 2018; 7(6):2641-53. doi: 10.1002/cam4.1517. pmid: 29733511
8.	Hoshi T, Watanabe MS, Watanabe H, et al. Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades. Biochem Biophys Res Commun 2019; 513(1):1-7. doi: 10.1016/j.bbrc.2019.02.015. doi: 10.1016/j.bbrc.2019.02.015 pmid: 30944079
9.	Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018; 391(10126):1163-73. doi: 10.1016/S0140-6736(18)30207-1. pmid: 29433850
10.	Kobayashi M, Kudo M, Izumi N, et al. Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan. J Gastroenterol 2019; 54(6):558-70. doi: 10.1007/s00535-019-01554-0. doi: 10.1007/s00535-019-01554-0 pmid: 30788569
11.	Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017; 389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. doi: 10.1016/S0140-6736(16)32453-9 pmid: 27932229
12.	Ogasawara S, Ooka Y, Itokawa N, et al. Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan. Invest New Drugs 2020; 38(1):172-80. doi: 10.1007/s10637-019-00801-8. doi: 10.1007/s10637-019-00801-8 pmid: 31172442
13.	Yoo C, Park JW, Kim YJ, et al. Multicenter retrospective analysis of the safety and efficacy of regorafenib after progression on sorafenib in Korean patients with hepatocellular carcinoma. Invest New Drugs 2019; 37(3):567-72. doi: 10.1007/s10637-018-0707-5. doi: 10.1007/s10637-018-0707-5 pmid: 30523474
14.	Ogasawara S, Chiba T, Ooka Y, et al. Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment. Invest New Drugs 2018; 36(2):332-9. doi: 10.1007/s10637-017-0507-3. doi: 10.1007/s10637-017-0507-3 pmid: 28891038
15.	Finn RS, Merle P, Granito A, et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. J Hepatol 2018; 69(2):353-8. doi: 10.1016/j.jhep.2018.04.010. doi: 10.1016/j.jhep.2018.04.010 pmid: 29704513
16.	Yang C, Qin S. Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma. Cancer Med 2018; 7(9):4570-83. doi: 10.1002/cam4.1664. doi: 10.1002/cam4.1664 pmid: 30109780
17.	Zhang H, Cao Y, Chen Y, et al. Apatinib promotes apoptosis of the SMMC-7721 hepatocellular carcinoma cell line via the PI3K/Akt pathway. Oncol Lett 2018; 15(4):5739-43. doi: 10.3892/ol.2018.8031. doi: 10.3892/ol.2018.8031 pmid: 29552208
18.	Yu WC, Zhang KZ, Chen SG, et al. Efficacy and Safety of apatinib in patients with intermediate/advanced hepatocellular carcinoma: A prospective observation study. Medicine (Baltimore) 2018; 97(3):e9704. doi: 10.1097/MD.0000000000009704.
19.	Xue JM, Astère M, Zhong MX, et al. Efficacy and safety of apatinib treatment for gastric cancer, hepatocellular carcinoma and non-small cell lung cancer: a meta-analysis. Onco Targets Ther 2018; 11:6119-28. doi: 10.2147/OTT.S172717. doi: 10.2147/OTT.S172717 pmid: 30288047
20.	Wang Y, Gou Q, Xu R, et al. Efficacy and safety of sorafenib versus apatinib in the treatment of intermediate and advanced hepatocellular carcinoma: a comparative retrospective study. Onco Targets Ther 2018; 11:3407-13. doi: 10.2147/OTT.S161023.
21.	Wang Y, Tang Z. A novel long-sustaining system of apatinib for long-term inhibition of the proliferation of hepatocellular carcinoma cells. Onco Targets Ther 2018; 11:8529-41. doi: 10.2147/OTT.S188209. doi: 10.2147/OTT.S188209 pmid: 30555243
22.	Liu Z, Wang C, Wu G, et al. MRI analysis of hydrogel-loaded apatinib for local therapy of hepatocellular carcinoma model in nude mice. Biochem Biophys Res Commun 2019; 509(2):529-34. doi: 10.1016/j.bbrc.2018.12.120. doi: 10.1016/j.bbrc.2018.12.120 pmid: 30598262
23.	Zhu Y, Feng B, Mei L, et al. Clinical efficacy of TACE combined with Apatinib in the treatment of advanced hepatocellular carcinoma. J BUON 2019; 24(2):608-14. doi: 10.1109/5.771073. pmid: 31128013
24.	Liu C, Xing W, Si T, et al. Efficacy and safety of apatinib combined with transarterial chemoembolization for hepatocellular carcinoma with portal venous tumor thrombus: a retrospective study. Oncotarget 2017; 8(59):100734-45. doi: 10.18632/oncotarget.20140. pmid: 29246017
25.	Lu W, Jin XL, Yang C, et al. Comparison of efficacy between TACE combined with apatinib and TACE alone in the treatment of intermediate and advanced hepatocellular carcinoma: A single-center randomized controlled trial. Cancer Biol Ther 2017; 18(6):433-8. doi: 10.1080/15384047.2017.1323589. doi: 10.1080/15384047.2017.1323589 pmid: 28548587
26.	Zhu AX, Finn RS, Mulcahy M, et al. A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res 2013; 19(23):6614-23. doi: 10.1158/1078-0432.CCR-13-1442. doi: 10.1158/1078-0432.CCR-13-1442 pmid: 24088738
27.	Chau I, Peck-Radosavljevic M, Borg C, et al. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study. Eur J Cancer 2017; 81:17-25. doi: 10.1016/j.ejca.2017.05.001. doi: 10.1016/j.ejca.2017.05.001 pmid: 28591675
28.	Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019; 20(2):282-96. doi: 10.1016/S1470-2045(18)30937-9. doi: 10.1016/S1470-2045(18)30937-9 pmid: 30665869
29.	Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008; 26(18):2992-8. doi: 10.1200/JCO.2007.15.9947. doi: 10.1200/JCO.2007.15.9947 pmid: 18565886
30.	Hubbard JM, Mahoney MR, Loui WS, et al. Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). Target Oncol 2017; 12(2):201-9. doi: 10.1007/s11523-016-0467-0. doi: 10.1007/s11523-016-0467-0 pmid: 27943153
31.	Thomas MB, Garrett-Mayer E, Anis M, et al. A randomized phase II open-label multi-institution study of the combination of bevacizumab and erlotinib compared to sorafenib in the first-line treatment of patients with advanced hepatocellular carcinoma. Oncology 2018; 94(6):329-39. doi: 10.1159/000485384. doi: 10.1159/000485384 pmid: 29719302
32.	Cheng AL, Kang YK, Lin DY, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 2013; 31(32):4067-75. doi: 10.1200/JCO.2012.45.8372. doi: 10.1200/JCO.2012.45.8372 pmid: 24081937
33.	Pokuri VK, Tomaszewski GM, Ait-Oudhia S, et al. Efficacy, Safety, and Potential Biomarkers of Sunitinib and Transarterial Chemoembolization (TACE) Combination in Advanced Hepatocellular Carcinoma (HCC): Phase II Trial. Am J Clin Oncol 2018; 41(4):332-8. doi: 10.1097/COC.0000000000000286. doi: 10.1097/COC.0000000000000286 pmid: 27014931
34.	Johnson PJ, Qin S, Park JW, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 2013; 31(28):3517-24. doi: 10.1200/JCO.2012.48.4410. doi: 10.1200/JCO.2012.48.4410 pmid: 23980084
35.	Llovet JM, Decaens T, Raoul JL, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 2013; 31(28):3509-16. doi: 10.1200/JCO.2012.47.3009. doi: 10.1200/JCO.2012.47.3009 pmid: 23980090
36.	Qu Z, Jiang C, Wu J, et al. Lenalidomide induces apoptosis and inhibits angiogenesis via caspase-3 and VEGF in hepatocellular carcinoma cells. Mol Med Rep 2016; 14(5):4781-6. doi: 10.3892/mmr.2016.5797. Epub 2016 Oct 5. doi: 10.3892/mmr.2016.5797 pmid: 27748917
37.	Maria de Souza C, Fonseca de Carvalho L, da Silva Vieira T, et al. Thalidomide attenuates mammary cancer associated-inflammation, angiogenesis and tumor growth in mice. Biomed Pharmacother 2012; 66(7):491-8. doi: 10.1016/j.biopha.2012.04.005. doi: 10.1016/j.biopha.2012.04.005 pmid: 22705333
38.	Shao YY, Chen BB, Ou DL, et al. Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy. Aliment Pharmacol Ther 2017; 46(8):722-30. doi: 10.1111/apt.14270. doi: 10.1111/apt.14270 pmid: 28815645
39.	Ye Q, Qin S, Liu Y, et al. Inhibitory effect of endostar on specific angiogenesis induced by human hepatocellular carcinoma. Gastroenterol Res Pract 2015; 2015:957574. doi: 10.1155/2015/957574. doi: 10.1155/2015/957574 pmid: 25983751
40.	Zhu AX, Ancukiewicz M, Supko JG, et al. Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study. Clin Cancer Res 2013; 19(6):1557-66. doi: 10.1158/1078-0432.CCR-12-3041. doi: 10.1158/1078-0432.CCR-12-3041 pmid: 23362324
41.	Kang YK, Yau T, Park JW, et al. Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. Ann Oncol 2015; 26(12):2457-63. doi: 10.1093/annonc/mdv388. doi: 10.1093/annonc/mdv388 pmid: 26386123
42.	Cainap C, Qin S, Huang WT, et al. Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol 2015; 33(2):172-9. doi: 10.1200/JCO.2013.54.3298. doi: 10.1200/JCO.2013.54.3298 pmid: 25488963
43.	Chen YJ, Chi CW, Su WC, et al. Lapatinib induces autophagic cell death and inhibits growth of human hepatocellular carcinoma. Oncotarget 2014; 5(13):4845-54. doi: 10.18632/oncotarget.2045. doi: 10.18632/oncotarget.2045 pmid: 24947784
44.	Chen JY, Huang WC, Wei CT, et al. The C-terminus of hepatitis B virus-encoded X protein is required for lapatinib sensitivity in hepatocellular carcinoma cells. Anticancer Res 2019; 39(2):721-6. doi: 10.21873/anticanres.13168. doi: 10.21873/anticanres.13168 pmid: 30711950
45.	Huether A, Höpfner M, Baradari V, et al. EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem Pharmacol 2005; 70(11):1568-78. doi: 10.1016/j.bcp.2005.09.007. doi: 10.1016/j.bcp.2005.09.007 pmid: 16226226
46.	Geng J, Li X, Lang X, et al. Combination of cetuximab and rapamycin enhances the therapeutic efficacy in hepatocellular carcinoma. Technol Cancer Res Treat 2014; 13(4):377-85. doi: 10.7785/tcrt.2012.500389. doi: 10.7785/tcrt.2012.500389 pmid: 24325131
47.	Zhang J, Zong Y, Xu GZ, et al. Erlotinib for advanced hepatocellular carcinoma. A systematic review of phase II/III clinical trials. Saudi Med J 2016; 37(11):1184-90. doi: 10.15537/smj.2016.11.16267. doi: 10.15537/smj.2016.11.16267 pmid: 27761555
48.	Zhu AX, Rosmorduc O, Evans TR, et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2015; 33(6):559-66. doi: 10.1200/JCO.2013.53.7746. doi: 10.1200/JCO.2013.53.7746 pmid: 25547503
49.	He L, Deng H, Lei J, et al. Efficacy of bevacizumab combined with erlotinib for advanced hepatocellular carcinoma: a single-arm meta-analysis based on prospective studies. BMC Cancer 2019; 19(1):276. doi: 10.1186/s12885-019-5487-6. doi: 10.1186/s12885-019-5487-6 pmid: 30922256
50.	Yanik EL, Chinnakotla S, Gustafson SK, et al. Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma. Liver Transpl 2016; 22(5):627-34. doi: 10.1002/lt.24395. doi: 10.1002/lt.24395 pmid: 26784951
51.	Geissler EK, Schnitzbauer AA, Zülke C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial. Transplantation 2016; 100(1):116-25. doi: 10.1097/TP.0000000000000965. doi: 10.1097/TP.0000000000000965 pmid: 26555945
52.	Zhu AX, Kudo M, Assenat E, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA 2014; 312(1):57-67. doi: 10.1001/jama.2014.7189. doi: 10.1001/jama.2014.7189 pmid: 25058218
53.	Koeberle D, Dufour JF, Demeter G, et al. Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). Ann Oncol 2016; 27(5):856-61. doi: 10.1093/annonc/mdw054. doi: 10.1093/annonc/mdw054 pmid: 26884590
54.	TCC Y, Lencioni R, Sukeepaisarnjaroen W, et al. A phase Ⅰ/Ⅱ multicenter study of single-agent foretinib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2017; 23(10):2405-13. doi: 10.1158/1078-0432.CCR-16-1789. doi: 10.1158/1078-0432.CCR-16-1789 pmid: 27821605
55.	Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med 2018; 379(1):54-63. doi: 10.1056/NEJMoa1717002. doi: 10.1056/NEJMoa1717002 pmid: 29972759
56.	Soto-Perez-de-Celis E, Aguiar PN, Cordón ML, et al. Cost-effectiveness of cabozantinib in the second-line treatment of advanced hepatocellular carcinoma. J Natl Compr Canc Netw 2019; 17(6):669-75. doi: 10.6004/jnccn.2018.7275. doi: 10.6004/jnccn.2018.7275 pmid: 31200357
57.	Ringelhan M, Pfister D, O’Connor T, et al. The immunology of hepatocellular carcinoma. Nat Immunol 2018; 19(3):222-32. doi: 10.1038/s41590-018-0044-z. doi: 10.1038/s41590-018-0044-z pmid: 29379119
58.	Facciorusso A, Licinio R, Carr BI, et al. MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2015; 9(7):993-1003. doi: 10.1586/17474124.2015.1040763. doi: 10.1586/17474124.2015.1040763 pmid: 25915713
59.	Tai WM, Yong WP, Lim C, et al. A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC). Ann Oncol 2018; 29(2):526. doi: 10.1093/annonc/mdx060. doi: 10.1093/annonc/mdx060 pmid: 28368515
60.	Lim HY, Heo J, Choi HJ, et al. A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma. Clin Cancer Res 2014; 20(23):5976-85. doi: 10.1158/1078-0432.CCR-13-3445. doi: 10.1158/1078-0432.CCR-13-3445 pmid: 25294897
61.	Lim HY, Merle P, Weiss KH, et al. Phase II studies with refametinib or refametinib plus sorafenib in patients with RAS-mutated hepatocellular carcinoma. Clin Cancer Res 2018; 24(19):4650-61. doi: 10.1158/1078-0432.CCR-17-3588. doi: 10.1158/1078-0432.CCR-17-3588 pmid: 29950351
62.	Abou-Alfa GK, Capanu M, O’Reilly EM, et al. A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma. J Hepatol 2014; 60(2):319-24. doi: 10.1016/j.jhep.2013.09.008. doi: 10.1016/j.jhep.2013.09.008 pmid: 24045151
63.	El-Khoueiry AB, O’Donnell R, Semrad TJ, et al. A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2018; 81(5):957-63. doi: 10.1007/s00280-018-3553-4. doi: 10.1007/s00280-018-3553-4 pmid: 29520435
64.	Scott LJ. Larotrectinib: First Global Approval. Drugs 2019; 79(2):201-6. doi: 10.1007/s40265-018-1044-x. doi: 10.1007/s40265-018-1044-x pmid: 30635837
65.	Liu D, Offin M, Harnicar S, et al. Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors. Ther Clin Risk Manag 2018; 14:1247-52. doi: 10.2147/TCRM.S147381. doi: 10.2147/TCRM.S147381 pmid: 30050303
66.	Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020; 21(2):271-82. doi: 10.1016/S1470-2045(19)30691-6. doi: 10.1016/S1470-2045(19)30691-6 pmid: 31838007
67.	Tomás-Loba A, Manieri E, González-Terán B, et al. p38γ is essential for cell cycle progression and liver tumorigenesis. Nature 2019; 568(7753):557-60. doi: 10.1038/s41586-019-1112-8. doi: 10.1038/s41586-019-1112-8 pmid: 30971822
68.	Chen DT, Pan JH, Chen YH, et al. The mu-opioid receptor is a molecular marker for poor prognosis in hepatocellular carcinoma and represents a potential therapeutic target. Br J Anaesth 2019; 122(6):e157-e167. doi: 10.1016/j.bja.2018.09.030. doi: 10.1016/j.bja.2018.09.030 pmid: 30915986
69.	Chan KK, Leung CO, Wong CC, et al. Secretory Stanniocalcin 1 promotes metastasis of hepatocellular carcinoma through activation of JNK signaling pathway. Cancer Lett 2017; 403:330-8. doi: 10.1016/j.canlet.2017.06.034. doi: 10.1016/j.canlet.2017.06.034 pmid: 28688970
70.	Moon H, Cho K, Shin S, et al. High risk of hepatocellular carcinoma development in fibrotic liver: role of the hippo-yap/taz signaling pathway. Int J Mol Sci 2019; 20(3):581. doi: 10.3390/ijms20030581.

[1]	张娜娜,李子健,朱海波. 去甲乌药碱：一种潜在的冠心病诊断心肌负荷药物[J]. Chinese Medical Sciences Journal, 2022, 37(3): 275-281.
[2]	杨万水, 蒋涵羽, 刘超, 魏靖伟, 周宇, 宫鹏云, 宋彬, 田捷. 多组学技术及其在肝细胞癌中的临床应用：当前进展与未来机遇[J]. Chinese Medical Sciences Journal, 2021, 36(3): 173-186.
[3]	李佳铮, 唐磊. 影像组学在抗肿瘤药物临床试验疗效评估中的应用和挑战[J]. Chinese Medical Sciences Journal, 2021, 36(3): 187-195.
[4]	杨广娥, 赵忠礼, 杨阳, 林丽, 宋丛磊, 汪晓翠, 杨斌. ATP1A3基因突变致儿童交替性偏瘫：2例病例报道[J]. Chinese Medical Sciences Journal, 2021, 36(2): 150-157.
[5]	吴坤荣, 张恕芳, 关紫菀, 李晓黎, 李蕊, 尹影, 李妍. 亚甲基四氢叶酸还原酶基因C677T多态性与中国2型糖尿病患者冠心病风险增加相关[J]. Chinese Medical Sciences Journal, 2021, 36(2): 103-109.
[6]	蒋平, 孙桃桃, 陈存武, 黄仁术, 钟枝梅, 娄新建, 刘港, 汪林, 左瑞华. 基于生物信息学分析肾透明细胞癌预后相关关键基因[J]. Chinese Medical Sciences Journal, 2021, 36(2): 127-134.
[7]	祖红林,侯骊坤,刘洪伟,詹渊博,何菊. 应用BITOLA系统筛选腹主动脉瘤与2型糖尿病相互作用的候选基因[J]. Chinese Medical Sciences Journal, 2021, 36(1): 50-56.
[8]	张帆, 钟斯然, 杨斯漫, 韦宇婷, 王竞静, 黄金兰, 吴登攀, 钟振国. 基于加权基因共表达网络分析阿尔茨海默病相关核心靶点[J]. Chinese Medical Sciences Journal, 2020, 35(4): 330-341.
[9]	崔旭蕾, 李旭, 李敏娜, 张越伦, 谢燚, 严唯刚, 张玉石, 纪志刚, 黄宇光. 超声引导下腰方肌阻滞可减少腹腔镜肾部分切除手术患者术后阿片类镇痛药物的用量[J]. Chinese Medical Sciences Journal, 2020, 35(4): 289-296.
[10]	刘超, 陈晓燕, 吴文齐, 竺晓凡. KDSR基因的纯合子突变可能导致1例患儿的角化异常和血小板减少[J]. Chinese Medical Sciences Journal, 2020, 35(3): 278-282.
[11]	许艳红,杨嘉,孟捷,王悍. 应用T1加权超微小氧化铁纳米颗粒进行早期肝癌靶向磁共振成像的体内外研究[J]. Chinese Medical Sciences Journal, 2020, 35(2): 142-150.
[12]	沈畅, 赵萌, 李芸云, 刘宁朴. 荟萃分析：亚甲基四氢叶酸还原酶基因C677T（MTHFR-C677T）多态性与糖尿病视网膜病变（DR）的关系[J]. Chinese Medical Sciences Journal, 2020, 35(1): 71-84.
[13]	陈雪,吕毅,吴荣谦. 合成生物传感器在疾病检测领域的应用技术进展：设计、分类和展望[J]. Chinese Medical Sciences Journal, 2018, 33(4): 240-251.
[14]	何琼, 王惠荟, 程涛, 袁卫平, 马钰波, 蒋永平, 任志华. CRISPR技术基因矫正乙型血友病来源iPS细胞的致病点突变并诱导肝系分化[J]. Chinese Medical Sciences Journal, 2017, 32(3): 135-144.
[15]	欧琴, 李文仿, 李蓓, 于春芳. 耐碳青霉烯类肺炎克雷白杆菌临床分布及整合素1与其耐药关系的研究[J]. Chinese Medical Sciences Journal, 2017, 32(2): 107-112.

优先出版

当期目次

过刊浏览

虚拟专题

作者中心

评阅者中心